Noom Partners With Waltz for GLP-1RAs; Seraxis Initiates Islet Cell Trial; Madrigal Completes MASH Outcomes Trial Enrollment
Here is a brief preview of this blast: Three cardiometabolic-related news items have been observed: Noom partners with Waltz Health for GLP-1RA cost savings (Noom press release; Waltz press release); Seraxis initiates SR-02 islet cell therapy trial in T1DM (view CT.gov record); Madrigal Pharmaceuticals announces MAESTRO-NASH OUTCOMES enrollment completion (view press release). Below, FENIX provides highlights and insights for the respective news items.